Selegiline

Selegiline is a selective monoamine oxidase B (MAO-B) inhibitor and active pharmaceutical ingredient used in the treatment of Parkinson's disease. Mediocon Inc supplies high-purity Selegiline API conforming to BP / EP / USP specifications from our GMP-certified facility in Aurangabad, Maharashtra, India.

Selegiline selectively inhibits MAO-B at therapeutic doses, preventing the breakdown of dopamine in the striatum and thereby extending dopaminergic activity. It is used as an adjunct to levodopa therapy in Parkinson's disease and has neuroprotective properties.

Key Features

• High-purity pharmaceutical grade API
• BP / EP / USP compliant
• Full CoA and MSDS documentation
• GMP certified manufacturing

Applications

• Parkinson's disease adjunct therapy
• MAO-B inhibitor formulations
• Neuroprotective pharmaceutical research
• Depression management (transdermal patch)

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings